Barclays PLC Purchases 39,267 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Barclays PLC raised its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 88.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,567 shares of the biotechnology company's stock after acquiring an additional 39,267 shares during the quarter. Barclays PLC owned approximately 0.27% of AnaptysBio worth $1,107,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of ANAB. Vanguard Group Inc. raised its holdings in AnaptysBio by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares during the period. Geode Capital Management LLC raised its stake in shares of AnaptysBio by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock worth $6,444,000 after buying an additional 21,196 shares during the period. Victory Capital Management Inc. lifted its position in shares of AnaptysBio by 41.0% during the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock valued at $4,428,000 after buying an additional 97,200 shares in the last quarter. Jennison Associates LLC grew its stake in shares of AnaptysBio by 1.6% during the 4th quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company's stock valued at $3,563,000 after acquiring an additional 4,242 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in AnaptysBio by 3.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 166,054 shares of the biotechnology company's stock worth $2,199,000 after acquiring an additional 5,733 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Wedbush reaffirmed an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a report on Thursday, May 1st. Johnson Rice reissued a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Guggenheim boosted their price objective on AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Wolfe Research initiated coverage on AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, AnaptysBio presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Stock Up 0.1 %

AnaptysBio stock traded up $0.01 during midday trading on Friday, reaching $19.59. 421,018 shares of the stock traded hands, compared to its average volume of 597,975. The stock has a market cap of $579.35 million, a P/E ratio of -3.22 and a beta of -0.20. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $41.31. The stock's fifty day moving average is $18.63 and its 200-day moving average is $18.59.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. On average, equities analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has initiated a stock repurchase plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 13.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.